Condition
Heterologous Immunity
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
100%
3 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 3 (2)
P 4 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04542330Phase 3Completed
Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
NCT04373291Phase 3Completed
Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic
NCT03400878Phase 4CompletedPrimary
Comparing Morbidity and Mortality Effects of Two Different Strains of BCG
Showing all 3 trials